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BACKGROUND: Novel prognostic biomarkers and therapeutic strategies are urgently required for malignant melanoma. Ecto-5-prime-
nucleotidase (NT5E; CD73) overexpression has been reported in several human cancers. The mechanism(s) underlying deregulated
expression and the clinical consequences of changes in expression are not known.
METHODS: We used RT–PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse expression and regulation of
NT5E in malignant melanoma cell lines and primary and metastatic melanomas.
RESULTS: NT5E is subject to epigenetic regulation in melanoma. NT5E mRNA is downregulated by methylation-dependent
transcriptional silencing in the melanoma cell lines SKMel2, SKMel23, WM35, Mel501, Mel505 and C81–61 and expression is
reactivated by azacytidine. In contrast, the CpG island is unmethylated and the gene expressed in cultured normal melanocytes. In
clinical cases of melanoma, methylation in the NT5E CpG island occurs in both primary and metastatic melanomas and correlates with
transcriptional downregulation of NT5E mRNA. Relapse with metastatic disease, particularly to the visceral sites and brain, is more
common in primary melanomas lacking NT5E methylation. Primary melanomas with methylation in NT5E show limited metastatic
potential or more commonly metastasise predominantly to nodal sites rather than viscera and brain (P¼ 0.01).
CONCLUSION: Deregulation of NT5E expression in melanoma occurs via epigenetic changes in the NT5E CpG island. Confirmation
of our results in larger clinical series would support the candidacy of NT5E as a clinical biomarker in melanoma, which could be
applied in both primary and relapsed disease. Inhibition of NT5E may have therapeutic potential in melanoma, particularly in patients
with more aggressive disease metastatic to viscera or the brain.
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Melanoma is an increasingly common, aggressive neoplastic
disorder of melanocytes, with a remarkable propensity to
disseminate and form metastases in distant organs sites, including
the bone, lungs, liver and brain. To date, no adjuvant therapy
after control of the primary tumour has shown clear benefit for
patients with high-risk primary melanoma and the prognosis for
patients with metastatic disease, particularly in visceral sites
and brain is frequently very poor. Despite empirical testing of
numerous chemotherapeutic regimens and targeted therapies,
melanoma remains an essentially incurable disorder in patients
with disseminated disease, with survival typically of a few months.
Early detection and effective treatment of melanoma at early stages
are urgently required, particularly as the incidence of the disease
increases and the demography relentlessly moves towards a young
patient group. The unique biology of the melanocyte and highly
individual pathobiology of melanoma implies that a large number
of genes may incur genetic or epigenetic change during the
development of melanoma.
Epigenetics is the study of changes in gene expression without
concomitant changes in gene structure and is now well recognised
as an important mechanism by which the expression of genes may
be modified in cancer (Lopez et al, 2009). Although the genome
undergoes a process of global hypomethylation during tumorigen-
esis, specific CpG islands become hypermethylated with associated
silencing of genes. Such methylation-dependent transcriptional
silencing is a common finding in many human tumours and
genes subject to this process are usually tumour suppressors.
Methylation of the majority of genes is specific to neoplasia.
Furthermore, methylated genomic DNA is stable and the
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technology for detection of methylated genomic DNA is sensitive
and readily amenable to automation. Taken together, these are
attractive properties for the use of methylated genomic DNA as a
disease biomarker, provided markers of sufficient specificity
for routine clinical use can be identified and their utility verified
in large patient populations.
Ecto-5-prime-nucleotidase (NT5E; CD73) has a number of
documented functions, the best characterised of which is catalysis
of the conversion of extracellular purine 50 mononucleotides to
membrane-permeable nucleosides, the preferred substrate being
AMP, resulting in local generation of adenosine. Evidence from a
number of experimental systems suggests that expression of NT5E
may be important in increasing the invasive and metastatic
properties of some cancer cells and overexpression of NT5E may
contribute to progression of cancer via generation of adenosine
(Wang et al, 2011). Further, NT5E-dependent production of
adenosine by cancer exosomes causes suppression of T-lympho-
cyte function (Clayton et al, 2011). Although these observations all
support an oncogenic role for NT5E, other properties may be
consistent with a potential tumour suppressor function. For example,
knockdown of NT5E increases cell migration in specific cell types
(Andrade et al, 2011). NT5E is overexpressed in some human
tumours, but the mechanism(s) causing overexpression have not
been defined. In the present study, we show that NT5E (CD73) is
subject to methylation-dependent transcriptional silencing in
melanoma, with potential clinical and therapeutic implications.
MATERIALS AND METHODS
Cell lines
Melanoma cell lines were routinely grown in Dulbecco’s modified
Eagles’s medium or Roswell Park Memorial Institute medium,
supplemented with 10% fetal bovine serum. Primary, normal
human melanocytes were purchased from Clonetics (Lonza Group,
Basel, Switzerland) and grown according to the manufacturer’s
instructions. All cells were incubated at 37 1C and 5% CO2, with
regular mycoplasma contamination test. The characteristics of the
cell lines are summarised in Table 1.
Demethylation
Demethylating treatment was as described previously (Lee et al,
2010). Briefly, cells were treated with 5-mM azacytidine
(AZA; Sigma, Gillingham, UK) for 7 days. Cells were split every
2–3 days with the addition of fresh drug. After drug treatment,
cells were harvested for qPCR.
Tissues
The study received approval from the Local Research Ethical
Committee, East London and City Health Authority and the Tayside
Tissue Bank under delegated authority from the Tayside Local
Research Ethics Committee. Tissues were obtained under written,
informed consent. Melanomas and control benign nevi were from
the Pathology archives of Bart’s and the London NHS Trust and
from the Tayside Skin Cancer Tissue Bank. All tissues underwent
histopathological review before inclusion in the study to (i) confirm
the diagnosis of melanoma; (ii) to confirm Breslow thickness (BT);
and (iii) to verify sufficient representation of neoplastic cells.
Melanomas were both primary, cutaneous melanomas and meta-
static lesions. Surgical excision was performed according to routine
protocols of clinical care. BT and melanoma sub-type is shown in
Figure 4 for the primary melanomas. Recurrent melanomas were
typically from lymph node resections, (where performed) sentinel
lymph node biopsies or cutaneous recurrences. Benign nevi were
from surgical excisions and confirmed by histopathological analysis
to contain no neoplastic cells.
Analysis of methylation
Genomic DNA was obtained from formalin-fixed paraffin-
embedded tissue sections by extended digestion in Proteinase K
followed by phenol extraction. Genomic DNA from cell lines and
tissue samples was subjected to bisulphite modification using the
EZ DNA Methylation Kit (Zymo, Irvine, CA, USA) according to
the manufacture’s instructions. Methylation in the CpG island of
the NT5E gene was analysed with pyrosequencing technology,
in which the degree of methylation at each CpG position in a
sequence is determined from the ratio of T and C, following bisul-
phite modification. Primer sequences were as follows: forward
50-GTATTAGGGTATTATTTGGTTTAT-30 reverse 50-BIOT-CTTACC
ACACTCTACCATCC-30 fragment size: 170bp.
Polymerase chain reaction conditions were as follows: 95 1C for
10min, 95 1C for 30 s/54 1C for 30 s/72 1C for 40 s for 40 cycles, 72 1C
for 7min. Polymerase chain reaction products were resolved through
2% agarose gels, visualised using a transilluminator, then analysed
by pyrosequencing using the Biotage Sample Prep kit and using the
forward primer for sequencing. Analysis of percentage methylation
at each CpG dinucleotide was performed using CpG Software
(Qiagen, Crawley, UK). Placental DNA was used as negative control
of methylation (0% average methylation) and a commercial
methylated DNA (Millipore, Watford, UK) was used as positive
control (98% average methylation). Methylation was also analysed by
methylation-specific PCR (MSP). DNA (0.5mg) was modified by
sodium bisulphite using the Zymo EZ DNA Methylation kit (Zymo).
Bisulfite-modified DNA was used as a template for PCR with primers
specific for methylated or unmethylated alleles. CpGenome Universal
Methylated DNA (Chemicon Europe, Chandlers Ford, Hampshire,
UK) and normal human unmethylated DNA were used as positive
and negative controls, respectively, in each experiment. MSP primer
sequences: M forward primer: 50-TATTTTATGAACGTTTTGCGTTA
CG-30 M reverse primer: 50-CTAAACTTACCACACTCTACCATCC
G-30 U forward primer: 50-ATTTTATGAATGTTTTGTGTTATGA-30
U reverse primer: 50-AACTTACCACACTCTACCATCCACT-30.
Gene expression
For qPCR analysis of expression, total RNA was isolated musing
the Recover All Total Nucleic Acid Isolation (Ambion, Life
Technologies Italia, Monza, Italy). In all, 25 ml PCR reactions were
performed using 50 ng of cDNA obtained by reverse transcription.
Table 1 Characteristics of melanoma cell lines
Cell line Description B-raf/N-ras NT5E
HEMA Normal human melanocytes Wt/Wt U
SBCL2 RGP Wt/Q61L U
PMWK Early RGP Wt/Wt U
WM-35 RGP V600E/Wt M
WM-902B SSM VGP V600E/Wt U
Mel224 VGP Wt/Q61R U
Mel505 VGP Wt/Wt M
WM-266-4 Metastatic melanoma V600D/Wt U
SKMel2 Metastatic melanoma Wt/Q61R M
SKMel23 Metastatic melanoma G466A/Wt M
SKMel28 Metastatic melanoma V600E/Wt U
SKMel30 Metastatic melanoma Wt/Q61R U
SKMel147 Metastatic melanoma Wt/Q61R U
SKMel173 Metastatic melanoma Wt/Q61K U
Mel501 Metastatic melanoma V600E/Wt M
COLO-829 Metastatic melanoma V600E/Wt U
C81-61 Metastatic melanoma Wt/Wt M
C8161 Metastatic melanoma Wt/Wt U
Abbreviations: M¼methylated; RGP¼ radial growth phase; SSM¼ superficial
spreading melanoma; U¼ unmethylated; VGP¼ vertical growth phase melanoma;
Wt¼wild-type.
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Amplification and analysis were done according to the manufac-
turer’s protocol in 96-well plates in an ABI PRISM 7000 Sequence
Detection System (Applied Biosystems, Life Technologies Italia,
Monza, Italy) and the pre-cast ‘TaqMan Gene Expression Assays’
(Applera, https://products.appliedbiosystems.com/) for NT5E
(Hs001573922_m1). Quantification of the target transcript was
performed in comparison to the reference transcript b2micro-
globulin (Hs99999907_m1), using the ‘delta-delta Ct method for
comparing relative expression results in real-time PCR as outlined
by PE Applied Biosystems (Perkin Elmer, Forster City, CA, USA).
Statistics
NT5E CpG island methylation status and presence or types of
metastasis were assessed for associations with the Fisher’s exact
test. All of the statistical analyses were performed using Prism
5 (GraphPad software, Inc., La Jolla, CA, USA).
RESULTS
NT5E expression is deregulated in highly metastatic
C8161 melanoma cells by loss of CpG island methylation
from the parental C81–61 cells
We analysed expression of NT5E mRNA in the paired malignant
melanoma cell lines C81–61 (low metastatic potential) and the
highly metastatic isogenic derivative C8161 (high metastatic
potential). We also analysed expression in three additional
melanoma cell lines and in normal human melanocytes. NT5E
mRNA was abundantly expressed in normal melanoyctes, in C8161
cells and in each of the three other melanoma cell lines. However,
expression was not detectable by RT–PCR in C81–61 cells
(Figure 1A). A CpG island is located at the 50 end of the NT5E
gene (Figure 1B). To test whether aberrant methylation might
be the basis for the low expression of NT5E mRNA in C81–61,
we performed bisulphite sequence analysis of the CpG island
in C81–61 (absent expression) and the C8161 derivative (high
expression). The CpG island was entirely unmethylated in C8161
but densely methylated in C81–61, consistent with aberrant
methylation underlying the absence of expression (Figure 1B).
On the basis of these observations, we designed primers for MSP
and analysed methylation in the cell lines. Methylation was only
observed in C81–61 consistent with bisulphite sequencing and
absence of expression in this cell line (Figure 1A). To further verify
that methylation is the mechanistic basis for NT5E downregula-
tion, we treated C81–61 and C8161 cells with the demethylating
agent AZA and measured mRNA levels. NT5E mRNA was
increased by AZA in C81–61 but not in C8161 (Figure 1C).
NT5E is frequently methylated in melanoma cell lines
We next analysed NT5E expression in a panel of additional
melanoma cell lines. By RT–PCR, NT5E mRNA was expressed in
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Figure 1 NT5E expression is silenced by methylation in C81–61 cells, but deregulated in highly metastatic isogenic C8161 cells. (A) Expression of NT5E
correlates inversely with CpG methylation in C81–61 and C8161. The upper panels are RT–PCR analysis of NT5E and the control gene GAPDH in five
melanoma cell lines and normal human melanocytes (NHEM) as indicated. NT5EmRNA is expressed abundantly in all cell lines except C81–61. Lower panels
are MSP analysis of the NT5E CpG island in the same cell lines. There is complete methylation in C81–61 but no detectable methylation in C8161.
(B) Bisulphite sequencing analysis of the NT5E CpG island in C81–61 and C8161 cell lines. Bisulphite sequencing was performed as described in Materials and
Methods and the figure shows a diagrammatic representation of the NT5E CpG island. CpG sites are shown as vertical lines. Methylated CpG dinucleotides
are shown as black blocks, unmethylated CpGs as open blocks. Five levels of methylation are indicated: 0-no black blocks; 1–25%-1 black block; 25–50%-2
black blocks; 50–75%-3 black blocks; 75–100%-4 black blocks. Positions of the MSP and bisulphite-sequencing primers are indicated. The CpG island is almost
completely methylated in C81–61 cells and entirely unmethylated in C8161, consistent with expression of NT5E mRNA in each cell line. (C) Expression of
NT5E mRNA is reactivated by demethylation. Exponentially growing C81–61, C8161 and Mel501 cells were treated with 50azacytidine (50 AZA) (black
blocks) or untreated (open blocks). cDNA was prepared and expression of NT5E mRNA determined as described in Materials and Methods.
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the majority of the cell lines analysed but was undetectable in
Mel501 and present only at low levels in Mel505 and PMWK
(Figure 2A). To validate these observations, we performed analysis
of NT5E expression and methylation in an independent panel of
melanoma cell lines (which contained a subset of the lines analysed
by semi-quantitative methods) using qPCR and pyrosequencing.
Representative pyrograms are shown in Figure 3. In total, there
was methylation in 6/16 cell lines (C81–61 (bisulphite sequen-
cing), SKMel2, SKMel23, WM-35, Mel501 and Mel505; Table 1;
Figure 2B). There was a good correlation between the presence of
methylation in the NT5E CpG island and absent or reduced
expression of the mRNA (Figure 2C and D). As in C81–61 cells,
demethylation by exposure to AZA caused an increase in NT5E
mRNA levels in Mel501 cells (Figure 1C).
The NT5E CpG island is methylated in clinical cases
of melanoma
These results show that expression of NT5E is regulated
epigenetically in melanoma cell lines and prompted us to test
whether the NT5E CpG island is methylated in vivo. We first
analysed, using MSP, CpG methylation in a series of 52 unselected,
histologically confirmed melanomas. Consistent with studies in
cell lines, there was methylation in the NT5E CpG island in 22/52
(42%) biopsies, as detected by MSP. We validated the frequency of
methylation by performing pyrosequencing on a subset of the
cases analysed by MSP and this showed a concordance in 8/9
melanomas.
Methylation of NT5E is associated with specific
sites of metastasis
We further investigated methylation in clinical cases of melanoma
by analysis of a well-characterised series of primary and metastatic
melanomas using pyrosequencing. As controls, we first tested a
series of benign nevi. This revealed a mean % methylation of 8.3%
in the nevi. Accordingly, we designated a value of 9% as the cut off
for methylation in melanomas and proceeded to analyse NT5E
CpG methylation in 27 primary melanomas from various sun-
exposed sites (Figure 4). Methylation was detected in 8/27 cases
(29%), a frequency comparable to the initial series of cases
analysed by MSP. Methylation was more common in nonrelapsing
cases, although this did not reach statistical significance because of
the small number of cases (6/17 vs 2/10; P¼ 0.23). In the 10 cases
with subsequent metastatic relapse, five were in visceral sites (the
brain, liver, lung and parotid) and five in nonvisceral sites
(Figure 4). The NT5E CpG island was methylated in 0/5 cases with
visceral metastasis, whereas 2/5 cases with nonvisceral metastasis
were methylated in the NT5E CpG island (P¼ 0.16). We noted that
the two relapsing cases with methylation were both lymph node
metastases.
NT5E methylation protects against metastasis in
high-risk primary melanomas
The 27 initially analysed cases included 17 with a BT 42mm, of
which 8/17 had relapsed at the time of censor. Relapse was more
common in cases lacking NT5E methylation (1/8 methylated vs 7/8
unmethylated), although again because of the small number of
cases this difference did not reach statistical significance
(P¼ 0.13).
NT5E methylation in nodal/cutaneous metastases
predicts risk of visceral metastases
These results prompted us to further examine the apparent inverse
correlation between methylation in NT5E and visceral metastasis.
We performed pyrosequencing in 26 metastatic lesions from LN or
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cutaneous sites confirmed by histopathology to be malignant
melanoma, which arose in patients with a previous primary
melanoma (Figure 5). The NT5E CpG island was methylated in
6/26 cases, using the methylation cutoff of 9% previously
established in benign nevi. Metastasis to visceral sites, including
bladder, brain, lung and liver, occurred in 12 patients and in all 12
the NT5E CpG island in the sampled lymph node/cutaneous
metastasis was unmethylated (P¼ 0.01, OR¼ 19; Figure 5).
DISCUSSION
Despite advances in understanding of the fundamental biology of
the melanocyte and development of therapeutic agents, including
the BRAF inhibitor Vemurafenib and the monoclonal antibody
Ipilimumab, metastatic malignant melanoma remains an incurable
disease with a poor prognosis. As such, additional mechanistic
insights to growth and progression of melanoma and novel
therapeutic strategies are clearly required. Prognosis at diagnosis
of patients with primary melanomas is estimated largely by
histopathological parameters, such as BT, presence of ulceration
and lympho-vascular invasion, but the ability of these to accurately
predict clinical outcomes is limited. As such, molecular genetic
biomarkers would be valuable in assessing risk of metastatic
relapse to viscera and/or brain: events that are associated with
poor clinical outcomes. Similarly, initial relapse in cutaneous or
nodal sites is common. Such relapses are typically managed by
surgical excision. This is not only therapeutic but provides, as part
of routine clinical management a source of tissue for assessment of
prognosis, assuming robust biomarkers to predict the risk of later
metastatic relapse to viscera and/or brain can be identified. Such
biomarkers would be immensely useful to inform clinical manage-
ment of such patients. Here, we report that expression of NT5E
(CD73) is regulated epigenetically in malignant melanoma.
We show that expression is downregulated by aberrant methyla-
tion in the CpG island located in the 50 regulatory region of the
NT5E gene in melanoma cell lines and clinical melanomas, and we
present preliminary evidence that methylation in the NT5E CpG
island may have utility as a biomarker of risk of visceral/brain
metastasis, both in primary melanoma and in cutaneous and/or
nodal recurrence. To the best of our knowledge, this is the first
report of epigenetic regulation of this gene in human neoplasia,
although a single study has identified upregulation of NT5E by
chemical demethylation in a gastric carcinoma cell line, consistent
with methylation-dependent transcriptional silencing (Yamashita
et al, 2006).
In the initial studies, we showed that NT5E mRNA was
abundantly overexpressed in C8161 cells, which have a highly
invasive and metastatic phenotype, but was not expressed in
(isogenic) parental C81–61 cells, implying that deregulation of
NT5E contributes to the greater metastatic potential of C8161 cells.
Bisulphite sequencing and MSP revealed that the NT5E CpG island
was fully methylated in parental C81–61 cells but was unmethy-
lated in C8161. Taken together with reactivation of expression by
AZA, these findings imply that loss of methylation is the
mechanistic basis for deregulation of NT5E in C8161 cells. These
results not only support a role for NT5E in the more metastatic
phenotype of C8161 cells but are also consistent, in a wider
context, with mechanistic models in which epigenetic changes in
key genes contribute to malignant progression. More commonly in
neoplasia, methylation increases in the CpG islands of genes as
tumour suppressors are silenced and cancer cells acquire
progressively more malignant properties (Lopez et al, 2009).
NT5E, however, appears to be a gene in which absence of
methylation contributes to a more malignant phenotype. Previous
studies on the expression of NT5E have reported overexpression of
the gene in invasive melanoma cell lines (Sadej et al, 2006a, b). It
was, therefore, unexpected to find that the gene was silenced by
methylation in some melanoma cell lines. The selective pressure
favouring downregulation of NT5E in some cell lines is not
clear. However, it has been previously shown that NT5E mRNA
is upregulated during differentiation of melanoma cell lines
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(Kim et al, 2006). Further, knock-down of NT5E causes increased
cell migration in some cell types (Andrade et al, 2011). It is
therefore possible that, perhaps in early disease, methylation-
dependent silencing of NT5E might block differentiation and/or
promote migration in a subset of melanomas.
The studies of clinical melanomas revealed a frequency of NT5E
CpG methylation similar to cell lines, using MSP and pyrosequen-
cing. We show that methylation in both primary melanomas and in
cutaneous and lymph node metastases influences the clinical
behaviour of the disease, cases with methylation being less likely to
metastasise to visceral sites such as the lung and liver and brain,
whereas cases with methylation more commonly metastasise to
nodal sites. Of particular interest, in patients with primary
melanomas of BT 42mm, which are at high increased risk of
metastasis, methylation in the NT5E CpG island was associated
with a lower risk of metastasis to visceral sites and brain than cases
lacking NT5Emethylation. The potential biomarker utility of NT5E
methylation was also evident in relapsed/metastatic lesions from
cutaneous or nodal sites, cases with NT5E methylation being more
likely to subsequently metastasise to viscera or brain if the NT5E
CpG island was unmethylated. Such nonvisceral metastatic lesions
are typically treated as part of routine clinical management by
surgical resection and tissue obtained from these procedures
would clearly be amenable to analysis of biomarkers such as NT5E.
As normal stromal skin tissue also expresses high levels of NT5E
(http://www.proteinatlas.org/ENSG00000135318), immunohisto-
chemical analysis of NT5E may not be prognostically informative.
Importantly, we have shown in the present study that NT5E
methylation levels are low in normal melanocytes and benign nevi,
emphasising the specificity of NT5E methylation for neoplastic
melanocytes. In some cases, surgically excised melanomas contain
a significant normal tissue component, potentially limiting the
biomarker utility of detection of NT5E CpG methylation, but this
could be readily overcome by micro-dissection of tissue sections
before methylation analysis. The sensitivity of methylation analysis
and its specificity for neoplasia implies that NT5Emethylation may
be more informative than immunohistochemistry as a prognostic
biomarker. Studies to address this question are in progress.
Our results are consistent with animal models in which NT5E
overexpression is associated with aggressive behaviour of cancers
Neck
Primary site Type
NMM
Recurrence
Forearm
Abdomen
29.6
13.2
20.7
5.5
0.3
0.2
0.31
Back
SSMM
SSMM
SSMM
No
No
No
No
13.8Thigh 0.99 No
Back 1
Back 1
Arm 3
Back
Neck
9.3
0
Back 3.4
0
2
2
2.6
2.5
3.5
Shin
SSMM
MM
NMM
NMM
No
No
No
No
Back
Arm
8.7
8.0
0
4.0
3.7
Neck
NMM
SSMM
SSMM
No
No
No
No
7.1Toe
Knee 11
1.5
22.4Shoulder
Arm
SSMM
SSMM
LN
LN
Cheek 19.72.7 LN
2.2Skin
Knee 0
Lower limb NMM Li, LN
Arm 01.6 Cu
LN
4.2Back
Scalp 1
Chin 0
4.3
14.0
5.5
MM LN, Pa
0–5%
NoSSMM
MM
NoMM1.2
0.35
0.5
MM
7.5
NoNMM8.0
NoNMM10.0
NMM
1.8
2.2
MM3.5
LNMM4.9
MM
Lu, Li, SpMM5.6
BrSSMM10.0
Mean87654321BT
50–100%20–50%10–20%5–10%
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Figure 5 NT5E CpG methylation in cutaneous lesions or LN predicts
visceral vs nonvisceral sites of distant metastasis. Pyrosequencing was
performed as described in Materials and Methods. The level of methylation
is represented by the intensity of shading in the circles, each of which
represents an individual CpG dinucleotide in the amplified fragment.
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(Stagg et al, 2011) and in mouse models in which the growth of
primary tumours and formation of metastases are reduced in mice
lacking NT5E (Yegutkin et al, 2011). Aside from the potential
biomarker utility of NT5E, the likely role of NT5E in driving
metastatic disease in a proportion of cases implies that NT5E may be
a viable therapeutic target in melanoma, particularly in clinically
challenging cases with visceral and/or brain metastases. Evidence
from animal models suggests that inhibition of both host and
tumour cell NT5E has anti-cancer effects (Wang et al, 2011; Yegutkin
et al, 2011), emphasising the likely value of inhibition of NT5E. Our
results suggest that use of NT5E inhibitors should be informed, at
least in part, by analysis of the methylation status of the CpG island.
In conclusion, we show that methylation in the NT5E CpG island
is an important determinant of metastatic potential of malignant
melanoma. Confirmation of these results in larger, independent
series would support the candidacy of NT5E as a potentially
clinically useful epigenetic biomarker to inform management of
melanoma patients, particularly those with high-risk primary
lesions and in those with nodal and/or cutaneous recurrences/
metastases.
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